Condition: Bladder Cancer · Urothelial Carcinoma (UC) · Hematuria · Sponsor: Convergent Genomics, Inc.
This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Urology San Diego | Oceanside, California, United States | Active Not Recruiting |
| Genesis Research, LLC | San Diego, California, United States | Active Not Recruiting |
| Urology Associates of Silicon Valley | San Jose, California, United States | Active Not Recruiting |
| UroPartners, LLC | Chicago, Illinois, United States | Active Not Recruiting |
| UroPartners, LLC | Grayslake, Illinois, United States | Active Not Recruiting |
| UroPartners, LLC | Mount Prospect, Illinois, United States | Active Not Recruiting |
| UroPartners, LLC | Niles, Illinois, United States | Active Not Recruiting |
| UroPartners, LLC | Wheaton, Illinois, United States | Active Not Recruiting |
| Chesapeake Urology Research Associates | Hanover, Maryland, United States | Active Not Recruiting |
| Comprehensive Urology | Royal Oak, Michigan, United States | Active Not Recruiting |
| Sheldon J. Freedman MD LTD | Las Vegas, Nevada, United States | Active Not Recruiting |
| Manhattan Medical Research Practice | New York, New York, United States | Active Not Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07673016